Erenumab Co-Developed by Amgen and Novartis for Episodic Migraine Prevention
Pharmaceutical company, Amgen, has announced positive top-line results for erenumab from a global Phase 3, STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE). Erenumab is specifically designed to prevent migraine by blocking the receptor which is believed to have a critical role in mediating the incapacitating pain of migraine. Amgen stated, “The results of this study are important because they confirm the results from our previous studies and add to our body of research in episodic migraine. We look forward to working with regulatory authorities to pursue approval of erenumab and making this novel migraine prevention treatment available to patients and physicians.” (Excerpted from Nov. 16, 2016 /PRNewswire)
As always, the MediSphere team thanks all of our patients who participated in this very important drug trial. Participation in clinical trials is an imperative to making safe, effective drugs available to patients and physicians.
For more information visit:
http://wwwext.amgen.com/media/news-releases/2016/11/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-second-phase-3-study/
